Express Pharma

IPM clocks Rs 115,644 Crs in May 2017

3

The anti-diabetic market continued with a strong growth of 21 per cent valued at Rs 790 crores

The Indian Pharmaceutical Market (IPM) was valued at Rs 115,644 crores and the retail sector was valued at Rs 97,269 crores as of MAT May 2017 with a monthly value of Rs 9767 crores growing at seven per cent over last year.

Top 10 companies continued to have a 43 per cent share in the IPM and reflected a collective growth of eight per cent for the month with Lupin showing a strong growth (16 per cent) and an improved share over the last three months. Companies in the 11-20 and 21-30 bracket grew slower at six per cent and five per cent respectively. Three of the top 10 companies grew in double digits while five of them grew faster than the market. MSD grew by 23 per cent and showed the fastest growth among top 30 companies.

Snapshot of top 150 companies

20170731ep04
Source: QuintilesIMS TSA & SSA, May 2017
  • Top 10 companies constitute ~ 43 per cent share of IPM on MAT and month basis
  • The top 150 companies continue to account for 97 per cent of IPM on MAT and month basis
  • For both MAT and month, Top 20 companies contribute to 64 per cent
  • Growth of the top companies slowed down, highest growth is in the companies ranked between 31-40

Amongst the 11-20 companies, Pfizer (-9 per cent) and DRL (-3 per cent) reflected negative growth while Emcure (three per cent) grew slower than the market. Four of the 11-20 companies, Aristo (10 per cent), Glenmark (11 per cent), USV (11 per cent) and Micro Labs (11 per cent) grew in double digits.

Irrespective of the GST cloud, we do see a very strong trend for the Top 10 brands of IPM where all the brands valued at Rs 326 crores have shown strong double digit growth rates at 21 per cent over last year. Mixtard and Glycomet-GP continues to maintain at number one and two positions respectively where Mixtard shows robust growths at 21 per cent and Glycomet GP maintains consistency. Janumet, Spasmo Proxyvon and Lantus maintain their position in top five whereas we do see Prevenar entering Top 10 brands list in May 2017. Galvus Met has revived their growths for the month which has also improved its rank to number six compared to April. Other brands with remarkable growth are Lantus, Pan D, Betnovate, Udiliv, Istamet and Synflorix.

Top 40 Brands

20170731ep05
Source: QuintilesIMS TSA & SSA, May 2017
  • Mixtard continues to be the top brand with a MS of ~0.5%
  • Janumet, Duphaston and Spasmo Proxyvon + have shown phenomenal growths in May 2017
  • Other brands with remarkable growth are Lantus, Pan D, Betnovate, Udiliv, Istamet and Synflorix

With a 78 per cent share in the IPM, Indian companies continued to dominate in the month of May 2017 with a growth of eight per cent which is slightly better than market. MNCs reflected a six per cent growth for the month. However, top MNCs like Abbott (11 per cent), GSK (eight per cent) and Sanofi (nine per cent) grew faster than the market for the month. MSD (23 per cent) reflected a growth above 20 per cent for the fourth month in a row.

While acute therapies continue to hold a massive share of IPM with a 64 per cent contribution to the total market, the chronic therapies grew at a decent double digit growth of 11 per cent. While anti-infectives remains the largest super group on MAT basis, on a monthly basis anti-infectives has been stagnant and therefore cardiac and gastro intestinal move up to number one and two positions with eight per cent and six per cent growths respectively. Anti-diabetic continues very strong growth of 21 per cent valued at Rs 790 crores for the month. Amongst the top contributors, DPP IV Inhibitors and combination dominates at number one position with a robust 31 per cent growth. Except food supplements the other top contributors like Glimepiride+ Met, Insulin and Cough Prep have shown a strong 20 per cent growth rates for the month.

Therapy Trends

20170731ep06
Source: QuintilesIMS TSA & SSA, May 2017
  • Cardiac therapy and GI constitute the largest market share in IPM occupying 12 per cent share each
  • Anti diabetics and vaccine registered a growth of around 21 per cent and 16 per cent respectively for the same period last year
  • Hormones and oncology market have de-grown by eight per cent and three per cent respectively, while rest of the therapies grew over previous month

Cardiac therapy area is the number one therapy for the month, clocking a revenue of Rs 1195 crores with a growth rate of eight per cent. Amongst the top molecules of this segment, the plain molecules except Rosuvastatin and Olmesartan have shown de-growth for the month owing to impact of regulatory price reduction. However, we do see a good growth in combination molecules of Amlodipine Telmisartan and also with HCT with Telmi + HCT at 12 per cent followed by Amlodipine + Telmisartan at 20 per cent respectively.

Anti-infectives continued to be stagnant and showed a zero per cent growth in the month of May 2017, making it the only second therapy area other than Gynaec in top 10 to reflect a growth of less than four per cent for the month. It continued to be at the third position below gastro intestinal for the second consecutive month and was valued at Rs 1098 crores for the month of May 2017. Among large molecules Ceftriaxine Injectables (-10.2 per cent) and Cefixime Oral Solids (-6.7 per cent) and Piperacillin + Tazobactam (-0.6 per cent) showed a value de-growth for the month while only Meropenam (11.5 per cent) showed a double digit growth.

Gastrointestinals maintained its second rank for the second consecutive month with a revenue of Rs 1130 crores and continued to show a steady growth of eight per cent over SPLY. Pantoprazole + Domperidone continued to show a strong growth of 14.3 per cent with the top brand PAN-D growing impressively with 24 per cent growth for the month of May 2017. Pantoprazole oral solids (4.6 per cent) reflected growth slower than the therapy area for the month while Ranitidine Oral Solids (-12 per cent) continued it’s de-growth trend of the last few months. The Bacillus Clausii market continued its high growth trend with a 50 per cent value growth on the basis of many new launches.

Anti-diabetics continued to be the number four ranked therapy in IPM for the month of May 2017 growing at 21 per cent over SPLY. Amongst the Top 10 brands in entire IPM six brands belong to this category and all are growing robustly. While DPP4 inhibitors remains as the top contributor to the entire category we see SGLT2 inhibitor showing a massive growth of 134 per cent for the month. Except Metformin which has shown de-growth of two per cent we do see strong higher double digit growths across Top 10 molecules indicating expansion of this therapy. Teneligliptin and combinations have reflected a robust growth (51 per cent) with Top brands like Tenglyn (41 per cent) Dynaglipt (94 per cent) and Tenlimac (104 per cent).

Dermatology, the second fastest growing therapy area in IPM clocked a growth of 14.5 per cent SPLY with a value of Rs 701 crores. Emollients continues to be the largest sub category with a 12.5 per cent growth while Itraconazole remains to be the fastest growing molecule at robust 101 per cent growth for the month. Luliconazole amongst the newer entrants has made an entry amongst the Top 10 molecules in dermatology with 16.5 crore value for the month. All the top 10 brands of Itraconazole market are growing above 40 per cent growth rates with IT-MAC at number two position with highest growths of 176 per cent for the month.

Neurology grew at par with the market with a 7.2 per cent growth for the month over SPLY, Levetiracetam remained the largest molecule in the therapy area with a value of Rs 45 crores with a seven per cent growth for the month which has been declining over the last three months. Escitalopram + Clonazepam reflected a healthy growth of 15 per cent with a value of Rs 21 crores for the month while Betahistine grew strongly at 19 per cent. Plain Escitalopram was the only molecule in the top 10 to reflect a value de-growth to the tune of -2 per cent for the month while clonazepam also showed a stagnant growth of just one per cent.

Global (April 2017)

The global pharma market is valued at $1071 billion growing at 3.8 per cent. The US continues to dominate the market with 42 per cent market share with growth of 3.3 per cent.

Amongst the top market, India has moved a couple positions down and is ranked 11th. Only markets in the top markets with more than 10 per cent growth are Venezuela, India, Russia and Brazil. All Top 5 EU markets are de-growing as per April 2017 data.

Indian companies hold 1.4 per cent share in the global market as per April 2017 data. For the month of April 2017, the IPM showed growth and all top 10 companies showed growth. Top 10 companies contributed to 43 per cent market share in India.

Comments are closed.